Overview
The FDA and EMA have been developing their approaches to AI in GxP environments through guidance documents, regulatory actions, and collaborative initiatives. While both agencies recognize the transformative potential of AI, they have different approaches to regulation. The EMA tends to take a more conservative approach, while the FDA is more permissive, allowing for adaptive and generative AI systems with appropriate governance. However, both agencies emphasize risk-based approaches, data integrity, and lifecycle oversight. This guide explores how the FDA and EMA view AI systems in regulated GxP use cases.
https://www.gxptrainings.com/course-category/ai-in-gxp-trainings
The EMA’s Approach to AI in GxP
The EMA has been developing its regulatory framework for AI through multiple initiatives. The agency’s approach emphasizes risk-based assessment and compliance with existing GxP frameworks.
EMA Reflection Paper – The EMA’s reflection paper emphasizes that AI applications in manufacturing must comply with GMP and data integrity standards. Applications affecting clinical decisions or regulatory submissions require additional scrutiny .
Draft Annex 22 – This new EU GMP Annex provides a dedicated regulatory framework specifically for AI models in the GMP environment. It restricts dynamic, probabilistic, and generative models from critical GMP applications.
AI System Impact Assessment – Following ISO/IEC 42001, the EMA requires systematic evaluation of consequences on individuals, groups, and societies throughout the AI system lifecycle.
The FDA’s Approach to AI in GxP
The FDA has been more proactive in authorizing AI systems and developing guidance. The agency’s approach emphasizes risk-based validation and leveraging existing frameworks.
FDA Definition of AI – The FDA defines Artificial Intelligence as “a machine-based system that can, for a given set of human-defined objectives, make predictions, recommendations, or decisions influencing real or virtual environments” .
FDA 510(k) Pathway – A systematic analysis found that 76% of the over 950 AI/ML medical devices authorized as of mid-2024 were cleared through the 510(k) pathway, relying on demonstrating substantial equivalence to a predicate device .
Computer Software Assurance – The FDA has shifted from traditional CSV toward CSA, emphasizing risk-based approaches and critical thinking.
Joint EMA-FDA Guiding Principles
In January 2026, the EMA and FDA jointly published ten guiding principles for AI in drug development . While the document remains guidance rather than a regulatory framework, it provides a clear shared regulatory perspective .
Adherence to Standards – AI systems are expected to comply with relevant legal, ethical, technical, scientific, and regulatory standards, including GxP .
End-to-End Traceability – Data provenance, processing, and analytical decisions must be traceable, verifiable, and aligned with GxP expectations .
Risk-Based Validation – Performance assessments should account for model behavior, human-AI interaction, and the context in which the system is used .
Lifecycle Oversight – Validation is treated as an ongoing responsibility with regular monitoring and reassessment expected as data, models, and use cases evolve .
Detailed Course Breakdown
Course 1: Validating AI in GxP – A Comprehensive Training
This comprehensive training program provides a deep and practical understanding of how to validate, govern, and maintain AI systems in GxP-regulated environments. It integrates the latest regulatory frameworks, including EU GMP Annex 11, the new Draft Annex 22, FDA’s Computer Software Assurance Guidance, 21 CFR Part 11, and the ISPE GAMP Guide: Artificial Intelligence.
Scope: The program addresses the critical question: “How do you validate something that can learn?” It covers AI system classification and risk tiering, data governance, performance acceptance criteria, test data management, ongoing monitoring, drift detection, and retraining governance.
Description of Modules: The curriculum covers 25 comprehensive sections across six parts.
Target Audience:
- Validation Engineers and CSV Specialists
- Quality Assurance Professionals
- Data Scientists and AI/ML Engineers
- Regulatory Affairs Professionals
- IT and Cybersecurity Professionals
- Senior Management and AI Program Leaders
- Auditors and Inspectors
Pricing: $399.00 with group discounts available.
FAQ:
- How does the FDA view AI in GxP? The FDA takes a more permissive stance, allowing for adaptive and generative AI systems with appropriate governance and risk-based validation.
- How does the EMA view AI in GxP? The EMA takes a more conservative approach, restricting dynamic, probabilistic, and generative models from critical GMP applications through Draft Annex 22.
- What are the joint EMA-FDA guiding principles? In January 2026, the EMA and FDA jointly published ten guiding principles for AI in drug development, including adherence to standards, traceability, and risk-based validation .
- What is the ISPE GAMP Guide: Artificial Intelligence? The ISPE GAMP Guide: Artificial Intelligence bridges established GAMP concepts with the unique characteristics of AI systems in GxP environments.
- What is the difference between EMA and FDA AI regulation? The FDA is more permissive while the EMA is more conservative, but both emphasize risk-based approaches and data integrity.
Enroll Now: https://www.gxptrainings.com/courses/validating-ai-in-gxp-a-comprehensive-training/
Course 2: AI Management Systems (ISO/IEC 42001:2023)
This comprehensive training program encompasses the full spectrum of requirements for establishing, implementing, maintaining, and continually improving an Artificial Intelligence Management System (AIMS) as mandated by ISO/IEC 42001:2023 – the world’s first international standard for AI management systems.
Scope: The program covers organizational context, leadership and commitment, risk management, AI system impact assessment, resource management, AI system lifecycle controls, data governance, third-party relationships, performance evaluation, and continual improvement.
Description of Modules: The curriculum covers 10 comprehensive modules.
Target Audience:
- AI Providers, Producers, and Developers
- AI Customers and Partners
- Quality Assurance and Compliance Professionals
- IT and Data Science Teams
- Regulatory Affairs Personnel
- Competent Authorities and Policymakers
Pricing: $249.00 with group discounts available.
FAQ:
- What is ISO/IEC 42001:2023? ISO/IEC 42001:2023 is the world’s first international standard for Artificial Intelligence Management Systems.
- How does ISO/IEC 42001 align with FDA and EMA expectations? It provides a management system framework that supports regulatory compliance.
- Who should take this training? Any organization wishing to implement an AIMS.
- What is the time commitment for this training? Approximately 18-24 hours of training.
- How does this training support regulatory understanding? It covers risk management and impact assessment required by regulators.
Enroll Now: https://www.gxptrainings.com/courses/ai-management-systems-iso-iec-420012023/
Course 3: Designing AI Driven Workflows in Life Sciences
This self-directed training program is designed for the full range of life sciences roles, drawing on real world case studies, specific performance statistics, and proven frameworks.
Scope: The program covers AI applications across life sciences, including drug discovery, clinical trials, manufacturing, quality assurance, supply chain, and regulatory affairs.
Description of Modules: The curriculum covers six comprehensive modules.
Target Audience:
- Senior management
- Quality assurance professionals
- GxP operations leads
- Clinical operations managers
- Regulatory affairs specialists
- Manufacturing supervisors
- Supply chain planners
- R&D scientists
- Medical affairs teams
Pricing: $349.00 with group discounts available.
FAQ:
- How does this course address regulatory requirements? It covers validation protocols and regulatory submission requirements.
- What is the typical ROI for AI in life sciences? AI deployments have shown significant returns.
- What are the common pitfalls in AI workflow design? Common pitfalls include poor data quality and lack of clear regulatory requirements.
- Do I need programming skills to take this course? No.
- What certification do I receive? Learners will receive a dated, traceable certificate of completion.
Enroll Now: https://www.gxptrainings.com/courses/designing-ai-driven-workflows-in-life-sciences/
Course 4: AI for Life Sciences Professionals
This training program is designed to equip life sciences professionals with the practical knowledge needed to lead, manage, or contribute to AI initiatives. No prior programming or advanced mathematics is assumed.
Scope: This program covers foundational concepts including neural networks, machine learning types, deep learning, and Explainable AI.
Description of Modules: The curriculum covers:
- Artificial Intelligence defined in practical terms
- Distinguishing AI from traditional rule-based programming
- Neural networks, machine learning, and deep learning functions
- Key technological drivers transforming life sciences
- Real-world AI applications
- Strategic frameworks
- Phased AI adoption journey
- Ethical, regulatory, and validation challenges
Target Audience:
- Research scientists
- Clinical research associates
- Medical affairs professionals
- Laboratory managers
- Bioinformatics scientists
- Regulatory affairs professionals
- Healthcare providers
Pricing: $299.00 with group discounts available.
FAQ:
- Do I need programming skills to take this course? No.
- What is Explainable AI and why is it important? Explainable AI makes AI model decisions understandable to humans.
- What is the 3-Horizon Model? The 3-Horizon Model is a strategic framework for assessing AI adoption.
- What is the AI Maturity Map? The AI Maturity Map is a framework for evaluating organizational readiness.
- How does this course support regulatory understanding? It covers regulatory challenges related to AI.
Enroll Now: https://www.gxptrainings.com/courses/ai-for-life-sciences-professionals/
Course 5: Navigating Generative AI in Academic Research
This training program is designed to help researchers, students, and academic professionals navigate the opportunities and challenges of Generative AI in academic research.
Scope: This training covers the intersection of large language models and academic work.
Description of Modules: The curriculum covers:
- Generative AI usage growth in scientific literature
- Benefits of GenAI for researchers
- Specific risks including threats to academic integrity
- Established ethical frameworks
- Publisher policies
- Detection of AI-generated text
- Disclosure statement requirements
- Impact on education
Target Audience:
- Graduate students
- Early-career and established researchers
- Research integrity officers
- University educators
Pricing: $249.00 with group discounts available.
FAQ:
- Can AI be listed as an author? No.
- How does Generative AI impact research integrity? Generative AI can enable undisclosed AI-generated content.
- What is the Who, What, Where framework? This framework helps structure disclosure statements.
- How can researchers use Generative AI ethically? Ethical use requires transparency and following publisher policies.
- What are the limitations of AI-generated text detection? Detection tools may produce false positives or negatives.
Enroll Now: https://www.gxptrainings.com/courses/navigating-generative-ai-in-academic-research/
Get Your Team Offer
For organizations looking to enroll multiple participants, we offer specialized team packages and volume discounts. Please reach out to our partnership team to discuss your specific needs and scores.
Contact Us: https://www.gxptrainings.com/contact-us/
Author
